Each gene in the risk evaluator, PLXNA1 (Ho, 1988), MARCKSL1 (Egeland et al., 2019), IQGAP3 (Leone et al., 2021), PFN2 (Cui et al., 2016), PON1 (Bobin-Dubigeon et al., 2012), and TAK (Li et al., 2022), has been reported to be associated with the prognosis or progression of cancer. This evidence concerns the gene PFN2 and cancer.